Turn precision medicine into action

When you’re driven to improve cancer patients’ lives, turn to a leader in oncology clinical trial development.

Through CerbACT, our immuno-oncology Center of Excellence, we empower precision medicine research by applying deep and wide biomarker expertise, translational research, and clinical development strategy.

From our purpose-built lab facility in Taiwan, CerbACT Asia supports I/O drug developers globally with cutting edge technology in FCM, histopathology, immunohistochemistry, and NGS sequencing, to turn precision medicine into action.

CerbACT is a joint venture between Cerba Research and ACT Genomics, developed to meet the needs of IO drug developers. A synergistic combination of expertise and capabilities to solve precision medicine challenges by advancing your research with a new platform combining deep scientific expertise and technical capabilities. For biotech, pharmaceutical, government, and non-government organizations, CerbACT turns precision medicine innovation into action.